放射線療法を受けているステージI〜IVの非小細胞肺がんまたは食道がんの患者とその介護者の身体能力と生活の質を改善するためのダイアディックヨガ介入
放射線療法を受けている患者とその家族の介護者の身体能力、症状、生活の質を管理するためのダイアディックな行動介入
This trial studies how well dyadic yoga intervention works in improving physical performance and quality of life in patients with stage I-IV non-small cell lung or esophageal cancer undergoing radiotherapy and their caregivers. Dyadic yoga intervention may help to improve physical function, fatigue, sleep difficulties, depressive symptoms, and overall quality of life for patients with non-small cell lung cancer and/or their caregivers.
調査の概要
状態
条件
- ステージ IVA 肺がん AJCC v8
- ステージ IVB 肺がん AJCC v8
- 肺非小細胞がん
- ステージ III 肺がん AJCC v8
- ステージ IV 肺がん AJCC v8
- ステージ II 肺がん AJCC v8
- ステージ IIA 肺がん AJCC v8
- ステージ IIB 肺がん AJCC v8
- ステージ IIIA 肺がん AJCC v8
- ステージ IIIB 肺がん AJCC v8
- 食道癌
- ステージ I 肺がん AJCC v8
- ステージ IA1 肺がん AJCC v8
- ステージ IA2 肺がん AJCC v8
- ステージ IA3 肺がん AJCC v8
- IB 期の肺がん AJCC v8
- ステージ IIIC 肺がん AJCC v8
詳細な説明
PRIMARY OBJECTIVE:
I. To examine the extent to which the yoga program improves patient physical performance (i.e., 6-minute walk test [6MWT]) as compared to the education group.
SECONDARY OBJECTIVE:
I. To examine the extent to which the yoga program improves patient and caregiver quality of life (QOL) (SF-36) compared to the education group.
TERTIARY OBJECTIVES:
I. To explore if, compared to the education group, the yoga program improves symptom burden, reduces inflammatory cytokine and cortisol rhythmicity dysregulation, and improves dyadic symptom management skills at the end of treatment, which will in turn mediate intervention outcomes at the subsequent follow-up assessments.
II. To explore if baseline factors such as depressive symptoms moderate the treatment response. We also seek to explore if baseline factors such as depressive symptoms moderate the treatment response.
QUALITATIVE OBJECTIVE:
I. To understand the patient and caregiver experience of cancer, cancer treatment, and experience in the behavioral interventions, and explore emerging themes as possible mediators. We would also like to understand participants feedback on participating in this intervention via mobile application (app) delivery.
OUTLINE: Patients and caregivers are assigned to 1 of 2 groups.
GROUP I: Patients and caregivers undergo dyadic yoga intervention session involving physical exercises and relaxation techniques over 60 minutes each for up to 15 sessions.
GROUP II: Patients and caregivers undergo dyadic education program session focusing on strategies of how to manage patient and caregiver symptoms over 60 minutes each for up to 15 sessions.
After completion of study, patients and caregivers are followed up every 2 weeks for 3 months and then every month for up to 6 months.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Kathrin Milbury
- 電話番号:713-745-2868
- メール:kmilbury@mdanderson.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- M D Anderson Cancer Center
-
コンタクト:
- Kathrin Milbury
- 電話番号:713-745-2868
- メール:kmilbury@mdanderson.org
-
主任研究者:
- Kathrin Milbury
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- PATIENT ONLY: Diagnosed with stage I-IV non-small cell lung cancer (NSCLC) or esophageal cancer and going to receive at least 3 weeks of thoracic radiotherapy (RT)
- PATIENT ONLY: Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
- PATIENT ONLY: Able to read, write and speak English
- PATIENT ONLY: Able to provide informed consent
- PATIENT ONLY: Having a family caregiver (e.g., spouse, sibling, adult child) who assists the patient during the cancer treatment (e.g., emotional support, transportation, meal preparation, care coordination, etc) per patient self-report. Note, patients must identify a family caregiver; however, the participation of the family caregiver is optional. For caregivers to be eligible, they must be at least 18 years old; able to read, write and speak English; and able to provide informed consent. Family caregivers may consent to participate in the intervention and caregiver assessments or only the assessments based on their preference.
Exclusion Criteria:
- PATIENT ONLY: Who have regularly (self-defined) participated in a mind-body practice in the year prior to diagnosis
- PATIENT ONLY: Patients who metastatic disease involving the central nervous system
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Group I (dyadic yoga)
Patients and caregivers undergo dyadic yoga intervention session involving physical exercises and relaxation techniques over 60 minutes each for up to 15 sessions. |
Ancillary studies
他の名前:
Ancillary studies Undergo dyadic yoga
他の名前:
|
|
アクティブコンパレータ:Group II (dyadic education)
Patients and caregivers undergo dyadic education program session focusing on strategies of how to manage patient and caregiver symptoms over 60 minutes each for up to 15 sessions. |
Ancillary studies
他の名前:
Ancillary studies Undergo dyadic education program
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient 6-minute walk test (6MWT)
時間枠:At 3 months post study
|
Descriptive statistics for study variables and potential covariates will be computed and distribution characteristics of the variables will be examined. The difference between dyadic yoga (DY) and dyadic edication (DE) at 3 month follow-up (3MFU) will be tested at a two-sided .05 significance level. |
At 3 months post study
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient and caregiver quality of life (QOL)
時間枠:Up to 6 months post study
|
Analyses will be similar to those for the primary outcome, except that we will use a dyadic model assuming additional dependence in outcomes between patient and caregiver outcomes. |
Up to 6 months post study
|
協力者と研究者
捜査官
- 主任研究者:Kathrin Milbury、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2018-0503
- 2018-0503 (その他の識別子:M D Anderson Cancer Center)
- NCI-2018-03913 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- R37CA231522 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。